MYOGEN INC. OC-COM DL-001

Gruß DB

heute nach Meldungen 50% vorbörslich im Plus.

siehe Posting #1 16.06.2005 Takeda Pharmaceuticals kaufen Zürcher Kantonalbank hier klicken zur Chartansicht Thomas Germann, Analyst der Zürcher Kantonalbank, empfiehlt die Aktie von Takeda Pharmaceuticals (ISIN JP3463000004/ WKN 853849) unverändert zum Kauf. Für das Gesamtjahr 2004 habe Japans größter Pharmakonzern ein Gewinnwachstum von gut 16% bei einem um 3,6% höheren Umsatz verzeichnen können. Für das gute Abschneiden seien unter anderem die weiterhin positiven Resultate der Hauptmedikamente Actos (Diabetes) und Blopress (Bluthochdruck) verantwortlich. Aber auch über die Produktpipeline habe Takeda Pharmaceuticals erfreuliches zu berichten: Ramelteon (Schlafstörung) und Luboprostin (Verstopfung) dürften noch dieses Jahr lanciert werden, und wichtige Präparate in den Bereichen Diabetes und Krebs hätten die nächste Entwicklungsphase erreicht. Zudem habe kein Wirkstoff aus der Pipeline gestrichen werden müssen. Positiv überraschen könnte Ramelteon: Der US-Markt werde momentan auf rund 2,2 Mrd. USD geschätzt; diese Zahl dürfte aber durch die Einführung mehrerer neuer Medikamente deutlich ansteigen. Takedas Präparat besitze den großen Vorteil, als einziges keine Abhängigkeit zu verursachen, und dürfte daher rund 20% des Marktes für sich beanspruchen. Takeda Pharmaceuticals sei angesichts der verbesserten Pipeline, der soliden Bilanz (Credit-Rating: AA) und des positiven Überraschungspotenzials deutlich unterbewertet (KGV 2006: 15,4x, Sektordurchschnitt rund 18x). Die Analysten der Zürcher Kantonalbank empfehlen den defensiven Wert von Takeda Pharmaceuticals weiterhin zum Kauf. Takeda Pharmaceuticals figuriere in ihrem Portfolio Pazifik. Und macht schon Gewinne, klar bei dem Kurs und wird in USA an der OTC gehandelt.

und ein Gap was noch nach oben zu schließen ist. Latest News (Printer friendly version) Eyetech Adopts Stockholder Rights Agreement NEW YORK, June 9, 2005 /PRNewswire-FirstCall via COMTEX/ -- Eyetech Pharmaceuticals, Inc. (Nasdaq: EYET), a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat diseases of the eye, today announced that its Board of Directors has approved a Rights Agreement under which its stockholders will receive a dividend in the form of preferred stock purchase rights. The Rights Agreement is similar to plans adopted by many other public companies and was not adopted in response to any current attempt to acquire the company. (Logo: http://www.newscom.com/cgi-bin/prnh/20050407/EYETLOGO ) The rights will be distributed at the rate of one right for each share of common stock owned by stockholders of record as of June 21, 2005. Each right will allow the holder to purchase one one-hundredth of a share (a unit) of Series A Preferred Stock at an initial purchase price of $150.00 under circumstances described in the Rights Agreement. The purchase price, the number of units of preferred stock and the type of securities issuable upon exercise of the rights are subject to adjustment. The rights will expire at the close of business on June 20, 2015 unless earlier redeemed or exchanged. Until a right is exercised, the holder thereof, as such, will have no rights as a stockholder of Eyetech, including the right to vote or to receive dividends. "The Rights Agreement is designed to assure that Eyetech's stockholders receive equal treatment in the event of any proposed takeover of Eyetech, and to guard against partial tender offers, squeeze-outs and other abusive tactics to gain control of Eyetech that could impair the Board's ability to represent stockholders' interests fully," said David R. Guyer, M.D., Chief Executive Officer and a director of Eyetech. "The Board believes the Rights Agreement is a sound and reasonable method for safeguarding stockholders' interests," Dr. Guyer added. "It is not intended to prevent an acquisition of the Eyetech on terms that are favorable, fair and in the best interests of all Eyetech stockholders, but rather to encourage any person seeking to acquire Eyetech to negotiate with the Board and to give the Board sufficient time to study and respond to any unsolicited attempts to acquire Eyetech." The rights are not immediately exercisable. Subject to the terms and conditions of the Rights Agreement, they will become exercisable ten business days after a person or group acquires, or commences a tender or exchange offer which would lead to the acquisition of, beneficial ownership of 15% or more of the outstanding common stock, subject to prior redemption or exchange. Once a person or group acquires beneficial ownership of 15% or more of the outstanding common stock, subject to the terms and conditions of the Rights Agreement, each right not owned by that person or group or certain related parties will entitle its holder to purchase, at the right's then-current purchase price, units of Series A Preferred Stock or, at the option of Eyetech, shares of common stock or cash, property or other securities of Eyetech having a market value equal to twice the then-current purchase price. Further details of the Rights Agreement are contained in a letter that will be mailed to all stockholders as of June 21, 2005. About Eyetech Pharmaceuticals, Inc. Eyetech Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat diseases of the eye. Eyetech's initial focus is on diseases affecting the back of the eye. Eyetech is commercializing and further developing Macugen(R) (pegaptanib sodium injection) with Pfizer Inc. for the treatment of neovascular AMD. Macugen is also being studied for the treatment of diabetic macular edema and retinal vein occlusion. Stichtag ist der 20.6.! Ehrlich gesagt habe ich noch nicht ganz verstanden was man bekommt One one hundred? Und dann 150 muß ich mir mal noch genauer durchlesen. in hurry gs Wer das schneller übersetzen kann, bitte um Aufklärung danke. Mal was ganz anderes. Dividende in Form von? Was? Bevorzugte Verkaufsoption?